- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00587379
Effect of Chronic Statin and Viagra Therapy in Persons With Endothelial Cell Dysfunction
January 12, 2012 updated by: Mayo Clinic
The Effect of Chronic Statin Therapy on Peripheral Arterial Tone Response to Sildenafil Citrate (Viagra), and on Erectile Function in Men With Coronary Artery Endothelial Cell Dysfunction
To determine if 6 weeks of daily treatment with Atorvastatin 40 mg alters the immediate effect of Sildenafil Citrate (Viagra, Pfizer Inc, New York, NY) on endothelial function (activity of the artery) as measured by noninvasive peripheral arterial tonography in men and women.
Also, to determine if 6 weeks of daily treatment with Atorvastatin 40 mg affects erectile function in men
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients undergoing coronary angiography
- No previous statin use
- Age > 18 years old
- No PDE5-1 use in the past 6 months
Exclusion Criteria:
- Patients with an Acute Coronary Syndrome
- Patients with Cardiogenic shock
- Patients > 30% coronary stenosis
- Patients with unexplained muscle pain
- Patients with acute liver disease
- Patients receiving immunosuppressant therapy, azoles, macrolide antibiotics, niacin, L-arginine
- Patients with serum creatinine > 2.0
- Patients with total cholesterol > 200 mmol/l
- Patients on current statin therapy or clinically indicated to be on statin therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
|
40 mg atorvastatin pill daily
|
Placebo Comparator: 2
Patients randomized to 1 40mg placebo pill per day for 6 week study
|
40 mg pill per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if endothelial function as measured by Peripheral Arterial Tonometry improves over a 6 week period while on Atorvastatin.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if treatment with Atovastatin affects erectile function in men
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (Actual)
May 1, 2008
Study Completion (Anticipated)
May 1, 2008
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
January 4, 2008
First Posted (Estimate)
January 7, 2008
Study Record Updates
Last Update Posted (Estimate)
January 13, 2012
Last Update Submitted That Met QC Criteria
January 12, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 328-04
- 2003-0359 - Pfizer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endothelial Dysfunction
-
M.D. Anderson Cancer CenterRecruitingEndothelial Dysfunction | Vascular | Endothelial | EndothelixUnited States
-
Clinica ARS MedicaUnknown
-
University of California, San DiegoCompletedEndothelial Dysfunction
-
M.D. Anderson Cancer CenterCompletedEndothelial DysfunctionUnited States
-
NestléCompleted
-
Société des Produits Nestlé (SPN)Completed
-
General Hospital of Chinese Armed Police ForcesChinese PLA General HospitalUnknown
-
University of ConnecticutCompletedEndothelial DysfunctionUnited States
-
Poznan University of Physical EducationNot yet recruitingEndothelial Dysfunction
-
Fundación para el Fomento de la Investigación Sanitaria...Recruiting
Clinical Trials on Atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown